Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Heart Journal

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ahj.2009.02.012PMID 19376306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up

  2009cited by this paper
• The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

  2008cited by this paper
• A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.

  2008cited by this paper
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

  2008cited by this paper
• Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

  2008cited by this paper
• 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2008cited by this paper
• Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.

  2008cited by this paper
• Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.

  2008cited by this paper
• Clinical ResearchInterventional CardiologyPoint-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reacti

  2008cited by this paper
• 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention

  2008cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

  2007cited by this paper
• Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

  2007cited by this paper
• Different methodologies for evaluating the effect of clopidogrel on platelet function in high‐risk coronary artery disease patients

  2007cited by this paper
• Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions

  2007cited by this paper
• Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

  2007cited by this paper
• Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study

  2007cited by this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cited by this paper
• Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

  2006cited by this paper
• Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.

  2006cited by this paper
• The difference between clopidogrel responsiveness and posttreatment platelet reactivity.

  2005cited by this paper
• Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study

  2005cited by this paper
• Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.

  2005cited by this paper
• Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy

  2004cited by this paper
• Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study

  2003cited by this paper
• A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

  1999cited by this paper
• A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting

  1998cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper

• In silico and In vivo approach to Discovery and Development Vanillin Derivatives as Anti-Thrombotic Agent

  2025cites this paper
• Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention

  2023cites this paper
• A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases

  2022cites this paper
• Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases

  2021cites this paper
• Antiplatelet Therapy

  2020cites this paper
• Farmakologická sekundární prevence nekardioembolického mozkového infarktu/ /tranzitorní ischemické ataky – současnost a budoucnost Pharmacological Secondary Prevention of Noncardioembolic Cerebral Infarction/transitory Ischemic Attack – Presence and future

  2020cites this paper
• The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes

  2019cites this paper
• Safety and Efficacy of the Pipeline Embolization Device Use in the Outside Circle of Willis Located Intracranial Aneurysms: A Single-Center Experience

  2019cites this paper
• Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).

  2019cites this paper
• Assessing the efficacy of aspirin and clopidogrel in patients with acute coronary syndromes

  2018cites this paper
• Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population

  2018cites this paper
• Anti-platelet drugs, pharmacogenomics and stent thrombosis : what's new? : commentary

  2017cites this paper
• Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome

  2017cites this paper
• Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes.

  2017cites this paper
• Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial

  2017cites this paper
• Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

  2017cites this paper
• P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists

  2017cites this paper
• Association of α2A-Adrenergic Receptor Genetic Variants with Platelet Reactivity in Chinese Patients on Dual Antiplatelet Therapy Undergoing Percutaneous Coronary Intervention.

  2017cites this paper
• Platelet dependent thrombosis, blood thrombogenicity and response to antiplatelet therapy in health, ageing and type 2 diabetes mellitus

  2016cites this paper
• Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

  2016cites this paper
• THE SUCCESS OF DIFFERENT APPROACHES TO THE DEVELOPMENT TO ANTIPLATELET DRUGS

  2016cites this paper
• Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy.

  2016cites this paper
• Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome

  2016cites this paper
• Platelet response to clopidogrel: the paradox of obesity or leanness?

  2015cites this paper
• Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy

  2015cites this paper
• Relationship of platelet indices with acute stent thrombosis in patients with acute coronary syndrome

  2015cites this paper
• Некоторые методы оценки экологического состояния почвенного покрова

  2015cites this paper
• A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study

  2015cites this paper
• Individual Platelet Adhesion (iPA): A novel assay of platelet function

  2014cites this paper
• P2Y12 Platelet Function Assay for Assessment of Bleeding Risk in Coronary Artery Bypass Grafting

  2014cites this paper
• Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value

  2014cites this paper
• Variability of on-treatment platelet reactivity in patients on clopidogrel

  2014cites this paper
• Monitoring and Reversal of Anticoagulation and Antiplatelets.

  2013cites this paper
• National Physician Qualification Program in Cardiovascular Disease Prevention and Integral Care.

  2013cites this paper
• High on-treatment platelet reactivity predicts cardiac events in patients with drug-eluting stents.

  2013cites this paper
• Clopidogrel "resistance": where are we now?

  2013cites this paper
• High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

  2013cites this paper
• Role of CYP450 in Antiplatelet Therapy: Considerations for Patients at Risk for Further Cardiovascular or Cerebrovascular Problems

  2013cites this paper
• Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department

  2013cites this paper
• Current Concepts in the Clinical Utility of Platelet Reactivity Testing.

  2013cites this paper
• Overview of platelet functional testing methods and their controversial role in the clopidogrel-treated patient

  2012cites this paper
• Therapeutic Drug Monitoring to Support Clinical Pharmacogenomics

  2012cites this paper
• Letter by Nezami et al regarding article, "Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial".

  2012cites this paper
• Pharmacogenomics of Cardiovascular Drugs

  2012cites this paper
• Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

  2012cites this paper
• Platelet function testing and the effect of natural products on platelet activation

  2012cites this paper
• The year in non-ST-segment elevation acute coronary syndrome.

  2012cites this paper
• Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.

  2012cites this paper
• Antiplatelet effect of aspirin in patients with coronary artery disease.

  2012cites this paper
• Pharmacogenetics of clopidogrel.

  2012cites this paper
• Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.

  2012cites this paper
• Platelet hyperreactivity and stent thrombosis in patients undergoing coronary stenting.

  2012cites this paper
• Novel treatments for cardiovascular disease prevention.

  2012cites this paper
• Stents and antiplatelet therapy.

  2012cites this paper
• Role of platelet reactivity in patients undergoing percutaneous coronary intervention

  2012cites this paper
• The Year in NonST-Segment Elevation Acute Coronary Syndrome

  2011cites this paper
• Review: Antiplatelet Therapy in Acute Coronary Syndromes

  2011cites this paper
• Antiplatelet options for secondary prevention in acute coronary syndromes

  2011cites this paper
• Phenotyping Patient-Derived Cells for Translational Studies in Cardiovascular Disease

  2011cites this paper
• Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

  2011cites this paper
• The pharmacogenetics of antiplatelet agents: towards personalized therapy?

  2011cites this paper
• Von Willebrand factor for predicting bleeding and mortality real deal or another failed biomarker?

  2011cites this paper
• Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT

  2011cites this paper
• Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention

  2011cites this paper
• Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.

  2011cites this paper
• Early double stent thrombosis associated with clopidogrel hyporesponsivenesss

  2011cites this paper
• The optimal pharmacological formula for percutaneous coronary intervention

  2011cites this paper
• Monitoring of antiplatelet therapy

  2011cites this paper
• Clinical Trials Update AHA Congress 2010

  2011cites this paper
• Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence

  2011cites this paper
• How to overcome aspirin and P 2 Y 12 blocker resistance in secondary prevention in high-risk patients ? -

  2011cites this paper
• Administration: Real Life Is Complicated Responding to the Clopidogrel Warning by the US Food and Drug

  2011cites this paper
• Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events

  2011cites this paper
• Clopidogrel: to test or not to test? That is the question--still.

  2011cites this paper
• Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention

  2011cites this paper
• Nonresponsiveness to Antiplatelet Therapy

  2011cites this paper
• Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention

  2011cites this paper
• Percutaneous Coronary Intervention and Concomitant Antithrombotic Therapy

  2011cites this paper
• P 2 Y 12 Assay : Impact on Thrombosis and Safety ( GRAVITAS ) Trial Intervention : A Time-Dependent Analysis of the Gauging Responsiveness With a Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary

  2011cites this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cites this paper
• The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines.

  2011cites this paper
• Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease

  2011cites this paper
• Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial

  2011cites this paper
• Role of platelet function testing in clinical practice: current concepts and future perspectives.

  2011cites this paper
• Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.

  2011cites this paper
• Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.

  2011cites this paper
• Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen

  2010cites this paper
• Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.

  2010cites this paper
• Antithrombotic treatment in acute coronary syndromes.

  2010cites this paper
• Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.

  2010cites this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cites this paper
• Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients

  2010cites this paper
• Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".

  2010cites this paper
• ATVB in Focus Platelets Unplugged: Focus on Platelet Biology

  2010cites this paper
• Platelet function testing and risk of bleeding complications

  2010cites this paper
• Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel

  2010cites this paper
• Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010

  2010cites this paper
• Poor response to clopidogrel: current and future options for its management

  2010cites this paper
• Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial data

  2010cites this paper
• Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence

  2010cites this paper